Condition category
Musculoskeletal Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Osteoporosis is a condition whereby the bones have lost strength and are at increased risk of fracture. It is well known to be underdiagnosed and undertreated. There are medications available that can significantly reduce the rate of fracturing but they are underused. The decision to treat is usually based on a fracture history and risk assessment, for example by measuring the bone mineral density (a measure of bone strength). The aim of this study was to test an educational model whereby a group of specially educated older peers could educate other seniors about the disease, its assessment and management, and assist them to navigate the healthcare system to get an assessment done and be placed on appropriate treatment by discussing the risk state with their family doctor.

Who can participate?
The study will be conducted in a limited geographic area in London Ontario, consisting of 13 apartment blocks with a high number of seniors. Anyone at or over the age of 65 and who is a resident of that community, can participate.

What does the study involve?
Participants will be randomly allocated to the intervention or the control group. Participants in the control group will receive usual care. Participants in the intervention group will attend a 2-hour education session presented by their peers, following which they will be assigned a monitor who will conduct a fracture risk assessment, encourage the subject to approach their doctor to obtain a bone mineral density (BMD) measurement, and with the result of the fracture risk assessment along with the BMD return to the physician for a final assessment on the need for treatment. The study will assess how many are successful at completing the assessment and being put on the appropriate medication.

What are the possible benefits and risks of participating?
The subjects may benefit from improvement in the management of their risk assessment if appropriate. There are no anticipated risks.

Where is the study run from?
At the University of Western Ontario, London, Ontario, Canada.

When is the study starting and how long is it expected to run for?
The study started in June 2008 and completed in September 2009.

Who is funding the study?
The study is funded by an unrestricted grant from the Alliance for Better Bone Health, an initiative of Procter and Gamble Pharmaceuticals.

Who is the main contact?
Dr Richard Crilly, Department of Medicine, University of Western Ontario.
Dr Marita Kloseck,

Trial website

Contact information



Primary contact

Prof Marita Kloseck


Contact details

The University of Western Ontario
Faculty of Health Sciences
N6A 5C1

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A randomised trial to determine if a peer-education model can improve the management of osteoporosis in community dwelling seniors


Study hypothesis

It is hypothesised that an education and mentoring model involving a small group of educated peer-mentors can increase the appropriate assessment and management of osteoporosis in a community of seniors.

Ethics approval

University of Western Ontario Research Ethics Board for Health Sciences, June 8, 2007, Research Number 12835E

Study design

Randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type

Quality of life

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet




A small group of six senior volunteers will be educated regarding osteoporosis, its assessment and management. They will then educate their peers regarding the disease and its assessment and management. Each subject is assigned a mentor who will conduct a fracture risk assessment.

The control was "usual care".

Intervention type



Not Applicable

Drug names

Primary outcome measure

The proportion of subjects who complete the process and receive appropriate management. The outcomes were recorded at baseline and 6 months.This was by patient interview with their mentor who recorded the patient's progress through the system. The nature of the study was a one on one mentor and patient relationship so progress through the system was continually monitored and advice offered if problems arose. The final assessment was at 6 months.

Secondary outcome measures

No secondary outcome measures

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Aged 65 or over, either gender, living within the Cherryhill apartment complex

Participant type


Age group




Target number of participants


Participant exclusion criteria

Inability to speak English

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

The University of Western Ontario
N6A 5C1

Sponsor information


Proctor and Gamble Pharmaceuticals Inc (Canada)

Sponsor details

4711 Yonge Street
M2N 6K8
+1 519 685 4021

Sponsor type




Funder type


Funder name

An unrestricted grant from the Alliance for Better Bone Health, an initiative of Proctor and Gamble Pharmaceuticals (bought out by Warner Chilcott after the funding) (Canada)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes